PG
NKTR icon

PEAK6 Group’s Nektar Therapeutics NKTR Stock Holding History

PEAK6 Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,327
Closed -$244K – 4762
2016
Q4 		$244K Sell
1,327
-4,406
-77% -$896K ﹤0.01% 3178
2016
Q3 		$1.48M Hold
5,733
– – 0.01% 1482
2016
Q2 		$1.22M Buy
5,733
+3,953
+222% +$884K 0.01% 1642
2016
Q1 		$367K Sell
1,780
-2,320
-57% -$446K ﹤0.01% 2568
2015
Q4 		$1.04M Sell
4,100
-5,847
-59% -$1.2M 0.01% 1900
2015
Q3 		$1.64M Buy
9,947
+960
+11% +$170K 0.01% 1735
2015
Q2 		$1.69M Buy
8,987
+3,987
+80% +$686K 0.01% 1612
2015
Q1 		$825K Buy
+5,000
New +$1.03M 0.01% 2082
2013
Q4 		– Sell
-133
Closed -$10K – 5258
2013
Q3 		$10K Buy
+133
New +$24.6K ﹤0.01% 4907

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PEAK6 Group's NKTR Position: Q1 2017 in Review

PEAK6 Group sold out of Nektar Therapeutics (NKTR) in Q1 2017, closing a stake of 880 shares — an estimated $162K sold.

PEAK6 Group first reported a position in NKTR in Q3 2013 and held it in 7 quarters. The position peaked at $488K in Q3 2015. 201 funds tracked by Wall St. Rank hold NKTR as of Q1 2017.

  • PEAK6 Group reported no remaining Nektar Therapeutics position as of Q1 2017 after selling out during the quarter.
  • PEAK6 Group sold 880 Nektar Therapeutics shares in Q1 2017, an estimated $162K.
  • PEAK6 Group first reported a position in Nektar Therapeutics in Q3 2013 and held it in 7 quarters.
  • PEAK6 Group's Nektar Therapeutics position peaked at $488K in Q3 2015.
  • 201 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2017.

Based on PEAK6 Group's 13F filing for Q1 2017, filed 15 May 2017.